Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
August 04, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 04, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) Approval of clinical trial for ABO-102 (AAV-SGSH) in European Union marks 3rd regulatory...
Abeona Therapeutics brinda información actualizada sobre los sujetos con síndrome de Sanfilippo tipo A inscritos inicialmente en el ensayo de genoterapia, que demuestra que las señales de biopotencia temprana son alentadoras
August 02, 2016 11:05 ET
|
Abeona Therapeutics
NUEVA YORK, NY Y CLEVELAND, OH--(Marketwired - 2 de agosto de 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)ABO-102 (AAV-SGSH) es la primera genoterapia basada en un virus adenoasociado (VAA)...
Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals
August 02, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy delivered by single...
Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
June 30, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - June 30, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based...
Abeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference
June 07, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - June 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based...
Abeona Therapeutics to Present at 2016 BIO International Convention
June 02, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY AND CLEVELAND, OH--(Marketwired - June 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and...
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)
May 24, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 24, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)
ABO-101 is Abeona's second AAV gene therapy to commence clinical trials in a rare CNS...
Abeona Therapeutics to Present at UBS 2016 Global Healthcare Conference
May 23, 2016 13:48 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 23, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene...
Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
May 17, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 17, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing products for severe and...
Abeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights
May 16, 2016 16:37 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene...